Hemolytic Disease of the Fetus and Newborn (HDFN) - Part 1

Definition: Hemolytic disease of the fetus and newborn is the destruction of fetal or neonatal red blood cells due to antibodies produced by the mother.
Historical Context: Formerly known as hemolytic disease of the newborn, the name has been expanded to include the fetus due to advancements in ultrasound and testing.
Mechanism: Shortened lifespan of fetal red blood cells is primarily caused by maternal antibodies binding to corresponding antigens on fetal red cells, leading to destruction.

Stimulation Sources: Maternal antibodies can be stimulated by previous pregnancies or blood transfusions.
Type of Antibodies: The focus is on immune antibodies produced through red cell stimulation.
Haemolysis Trigger: Haemolysis occurs when maternal antibodies bind to antigens on fetal red blood cells.

Hemolysis Rate: Determined by the specific antibody-antigen interactions on the red cells.
IgG Subtypes:
- IgG1 and IgG3: More efficient at causing hemolysis.
- IgG2 and IgG4: Less effective at hemolysis.

Placental Role:
- Acts as a barrier, facilitating oxygen, nutrient, and waste exchange between mother and fetus.
- Limits fetal cell access to maternal circulation, reducing antibody production risks during pregnancy.
Foreign Antigens: Fetal red cell antigens can elicit an immune response from the mother, leading to IgG antibody production.
Subsequent Pregnancies: IgG antibodies can cross the placenta and bind to fetal red cells, leading to destruction by macrophages in fetal organs (liver and spleen).

Delivery Concerns: Separation of the placenta at delivery can release fetal cells into maternal circulation, posing risks of hemolytic disorders.
Testing for Fetal Cells: Some methods include performing a fetal-maternal hemorrhage test in Rh-negative mothers or a Kleihauer-Betke test in Rh-positive mothers.
Trauma Awareness: Pregnant women should be assessed after trauma since it can lead to fetal cell exposure in maternal circulation.

Maternal Antigen Absence: Mother must lack the antigen present on fetal red cells to produce the corresponding antibody.
Fetal Antigen Development: Antigens on the fetal red cells must be well-developed at birth.
- Case of Lewis P1 antigen: Poorly developed at birth, resulting in no significant hemolysis risk.
IgG Antibody Production: Mother must produce IgG subclass antibodies, as they can cross the placenta.
Antigen Quantity: Sufficient levels of antigen must exist on fetal red cells for hemolysis to potentially occur.

Definition: Condition where fetal red cell destruction leads to increased production of red cells in the fetal bone marrow, resulting in immature forms (erythroblasts).
Blood Smear Observations: Nucleated red blood cells may be seen in peripheral blood smears.
Anemia Symptoms: Increased destruction rate leads to lower hemoglobin and hematocrit levels, causing anemia.

Definition: Abnormal fluid accumulation in multiple fetal compartments (ascites, pleural, or pericardial effusion).
Clinical Features: Presents with edema, hepatosplenomegaly, cardiac failure, respiratory distress.
Risks: Can lead to intrauterine or neonatal death.

Jaundice Monitoring: Increased bilirubin levels due to hemoglobin breakdown; the mother's liver handles this during gestation, but neonates often cannot process bilirubin effectively.
Kernicterus Risk: Elevated bilirubin levels (around 20 mg/dL) can cross the blood-brain barrier, potentially causing brain damage.

Direct Antiglobulin Test (DAT): A positive result indicates ongoing hemolytic activity, pointing to hemolytic disease of the fetus and newborn.

Primary Response: First-time exposure to blood group antigens via previous pregnancy or transfusion; the mother lacks the relevant antigen.
Secondary Response: Occurs in subsequent pregnancies, with existing antibodies crossing the placenta and targeting fetal red cells.

Anemia Consequences: Leads to increased cardiac output and potential heart failure due to hypoxia.
Enlargement of Organs: Increased demand for red cells results in hepatosplenomegaly and extramedullary hematopoiesis.

Antibody Titer Calculations: Positive antibody screens lead to further identification and monitoring of antibody titers.
Amniocentesis/Chorionic Villus Sampling: Used for examining fetal blood for hemoglobin, hematocrit, bilirubin levels, and potential antibody reactions.

Antigenic Variability: Some blood group antigens, such as Duffy, are less implicated in HDFN due to lower antigenicity compared to D and Kell.
Antigen Structure: The recognized structure and spacing of antigens on fetal red blood cells may influence the immune response rate.

Prenatal Testing: Review maternal blood bank history for previous pregnancies and possible sensitization.
Parental Phenotyping: Assess paternal blood type and potential antigen inheritance in the fetus, keeping in mind paternity considerations.
Blood Type Evaluations: Determining maternal blood type and ensuring proper antibody screening are crucial.

Prevalence: Most commonly observed in group O mothers having A or B infants due to naturally occurring antibodies.
Symptoms: Mild hemolysis, usually asymptomatic; may lead to hyperbilirubinemia or jaundice within the first 1-2 days after birth.
DAT Testing: Often negative or weakly positive; generally managed with phototherapy.

Severity: Responsible for the most severe cases of HDFN, prevalent in sensitized mothers with anti-D antibodies.
Mechanism: IgG antibodies cross placenta and bind to Rh-positive fetal cells, leading to significant hemolysis and anemia.
Diagnostic Differences: Strongly positive DAT in Rh cases compared to mild reactions in ABO cases.

Fetal-Maternal Hemorrhage: Risk factors include amniocentesis, abdominal trauma, and miscarriage, which can lead to fetal blood entering maternal circulation.
Host Genetic Factors: Certain RhD and RhCE genotype combinations increase likelihood of maternal immunization.
Threshold Antigen Exposure: Sensitization can occur with very small volumes of fetal red cell exposure, as little as 1 mL.

Other IgG Antibodies: Non-Rh non-ABO antibodies also implicated in HDFN but are less common and primarily ineffective due to IgM class characteristics.

Organ Enlargement: Commonly seen in Rh cases but typically absent in ABO cases due to less severe hemolysis.
Anemia Severity: Stronger evidence for anemia presence in Rh cases; varying degrees of miliary or weak results in ABO.
History Review: Important to differentiate initial versus subsequent pregnancies and their associated risks.
Spherocyte Identification: Examination for spherocytes in blood tests can be indicative of ongoing hemolysis and cellular changes post antibody binding.